FREE ACCESS

Sign in with Google to continue in the IIPLA Blog.

Google SSO gives you the quickest path into IIPLA analysis, reading access, and member-level continuity across articles. The full login page is still available if you prefer another option.

By continuing you agree to our terms and privacy policy.

Already have an account? Log in · Create account

Members-only content

IIPLA Blog
Wednesday, April 29, 2026
Licensing

GSK Gains $370 Million Upfront, Reduced Royalties in CureVac mRNA Patent Settlement Agreement with Pfizer, BioNTech

GSK benefits financially from a settlement with BioNTech, CureVac, and Pfizer over mRNA patent disputes, including upfront payments and future royalties.

IIPLA News Desk•anonymous access•0 articles left this week
GSK Gains $370 Million Upfront, Reduced Royalties in CureVac mRNA Patent Settlement Agreement with Pfizer, BioNTech
Sign In To Continue

You have reached the guest article limit.

Unlock more IIPLA analysis by signing in with SSO or joining as a member.

Sign in with SSOBecome a paid member
GSK benefits financially from a settlement with BioNTech, CureVac, and Pfizer over mRNA patent disputes, including upfront payments and future royalties.